• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers.

作者信息

Tober-Lau Pinkus, Schwarz Tatjana, Vanshylla Kanika, Hillus David, Gruell Henning, Suttorp Norbert, Landgraf Irmgard, Kappert Kai, Seybold Joachim, Drosten Christian, Klein Florian, Kurth Florian, Sander Leif Erik, Corman Victor Max

机构信息

Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, 13353 Berlin, Germany.

Institute of Virology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; German Centre for Infection Research, Partner Site Charité, Berlin, Germany.

出版信息

Lancet Respir Med. 2021 Nov;9(11):e104-e105. doi: 10.1016/S2213-2600(21)00456-2. Epub 2021 Oct 20.

DOI:
10.1016/S2213-2600(21)00456-2
PMID:34687656
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8528470/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d38/8528470/3d0760053cfa/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d38/8528470/3d0760053cfa/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d38/8528470/3d0760053cfa/gr1_lrg.jpg

相似文献

1
Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers.BNT162b2疫苗在老年人和年轻医护人员中的长期免疫原性。
Lancet Respir Med. 2021 Nov;9(11):e104-e105. doi: 10.1016/S2213-2600(21)00456-2. Epub 2021 Oct 20.
2
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.ChAdOx1 nCoV-19 和 BNT162b2 同源和异源加强免疫的安全性、反应原性和免疫原性：一项前瞻性队列研究。
Lancet Respir Med. 2021 Nov;9(11):1255-1265. doi: 10.1016/S2213-2600(21)00357-X. Epub 2021 Aug 13.
3
Heterologous ChAdOx1-nCoV19-BNT162b2 vaccination provides superior immunogenicity against COVID-19.异源ChAdOx1-nCoV19-BNT162b2疫苗接种对新冠病毒具有更强的免疫原性。
Lancet Respir Med. 2021 Nov;9(11):1207-1209. doi: 10.1016/S2213-2600(21)00366-0. Epub 2021 Aug 13.
4
Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.智利科兴和国药疫苗接种后动态 IgG 血清阳性率：哨点监测研究。
Lancet Infect Dis. 2022 Jan;22(1):56-63. doi: 10.1016/S1473-3099(21)00479-5. Epub 2021 Sep 9.
5
Persistent differences in the immunogenicity of the two COVID-19 primary vaccines series, modulated by booster mRNA vaccination and breakthrough infection.两种 COVID-19 基础疫苗系列免疫原性的持续差异，由加强 mRNA 疫苗接种和突破性感染调节。
Vaccine. 2024 Jul 25;42(19):3953-3960. doi: 10.1016/j.vaccine.2024.05.003. Epub 2024 May 9.
6
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.在英国，用 ChAdOx1 nCov-19 或 BNT162b2 接种两剂后作为第三剂（加强针）接种 7 种 COVID-19 疫苗的安全性和免疫原性（COV-BOOST）：一项盲法、多中心、随机、对照、2 期试验。
Lancet. 2021 Dec 18;398(10318):2258-2276. doi: 10.1016/S0140-6736(21)02717-3. Epub 2021 Dec 2.
7
Early Immunogenicity and Safety of the Third Dose of BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Among Adults Older Than 60 Years: Real-World Experience.60 岁以上成年人接种 BNT162b2 信使 RNA 新冠肺炎疫苗第三剂的早期免疫原性和安全性：真实世界经验。
J Infect Dis. 2022 Mar 2;225(5):785-792. doi: 10.1093/infdis/jiab584.
8
Immunogenicity Following Administration of BNT162b2 and Ad26.COV2.S COVID-19 Vaccines in the Pregnant Population during the Third Trimester.第三孕期孕妇接种 BNT162b2 和 Ad26.COV2.S COVID-19 疫苗后的免疫原性。
Viruses. 2022 Feb 2;14(2):307. doi: 10.3390/v14020307.
9
Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People.老年人接种两剂 BNT162b2 mRNA 疫苗后对 SARS-CoV-2 的功能性 T 细胞反应受损。
Front Immunol. 2021 Nov 16;12:778679. doi: 10.3389/fimmu.2021.778679. eCollection 2021.
10
Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.英格兰长期护理机构居民中 ChAdOx1 nCoV-19 与 BNT162b2 疫苗首针接种对 SARS-CoV-2 感染的疫苗有效性（VIVALDI）：一项前瞻性队列研究。
Lancet Infect Dis. 2021 Nov;21(11):1529-1538. doi: 10.1016/S1473-3099(21)00289-9. Epub 2021 Jun 23.

引用本文的文献

1
Factors Associated with Impaired Humoral Immune Response to mRNA Vaccines in Patients with Inflammatory Bowel Disease: A Matched-Cohort Analysis from the RisCoin Study.炎症性肠病患者对mRNA疫苗体液免疫反应受损的相关因素：来自RisCoin研究的匹配队列分析
Vaccines (Basel). 2025 Jun 23;13(7):673. doi: 10.3390/vaccines13070673.
2
Role of antiviral CD8+ T cell immunity to SARS-CoV-2 infection and vaccination.抗病毒CD8 + T细胞免疫对SARS-CoV-2感染和疫苗接种的作用。
J Virol. 2025 Apr 15;99(4):e0135024. doi: 10.1128/jvi.01350-24. Epub 2025 Mar 3.
3
Kinetics of pro- and anti-inflammatory spike-specific cellular immune responses in long-term care facility residents after COVID-19 mRNA primary and booster vaccination: a prospective longitudinal study in Japan.

本文引用的文献

1
Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine.与 SARS-CoV-2 突破性感染相关的时间。
Nat Commun. 2021 Nov 4;12(1):6379. doi: 10.1038/s41467-021-26672-3.
2
Waning Immunity after the BNT162b2 Vaccine in Israel.以色列接种 BNT162b2 疫苗后的免疫力下降。
N Engl J Med. 2021 Dec 9;385(24):e85. doi: 10.1056/NEJMoa2114228. Epub 2021 Oct 27.
3
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.
新型冠状病毒肺炎mRNA初次和加强疫苗接种后长期护理机构居民中促炎和抗炎刺突特异性细胞免疫反应的动力学：日本一项前瞻性纵向研究
Immun Ageing. 2024 Jun 22;21(1):41. doi: 10.1186/s12979-024-00444-1.
4
Functional antibody responses targeting the Spike protein of SARS-CoV-2 Omicron XBB.1.5 in elderly nursing home residents following Wuhan-Hu-1-based mRNA booster vaccination.针对基于武汉株 mRNA 加强针接种后老年疗养院居民中靶向 SARS-CoV-2 奥密克戎 XBB.1.5 的 Spike 蛋白的功能性抗体反应。
Sci Rep. 2024 May 24;14(1):11896. doi: 10.1038/s41598-024-62874-7.
5
Anti-spike protein IgG antibody responses up to 3 months after the third dose of the BNT162b2 mRNA vaccine in medical care workers.医护人员接种第三剂BNT162b2 mRNA疫苗后长达3个月的抗刺突蛋白IgG抗体反应。
J Gen Fam Med. 2024 Mar 26;25(3):140-145. doi: 10.1002/jgf2.688. eCollection 2024 May.
6
Kinetics of COVID-19 mRNA primary and booster vaccine-associated neutralizing activity against SARS-CoV-2 variants of concern in long-term care facility residents: a prospective longitudinal study in Japan.长期护理机构居民中COVID-19 mRNA 初免和加强疫苗对关注的SARS-CoV-2变异株的中和活性动力学：日本的一项前瞻性纵向研究
Immun Ageing. 2023 Aug 17;20(1):42. doi: 10.1186/s12979-023-00368-2.
7
Antibody response to inactivated COVID-19 vaccine in patients with type 2 diabetes mellitus after the booster immunization.2 型糖尿病患者加强免疫后对灭活 COVID-19 疫苗的抗体反应。
J Diabetes. 2023 Nov;15(11):931-943. doi: 10.1111/1753-0407.13448. Epub 2023 Jul 30.
8
Interoperable, Domain-Specific Extensions for the German Corona Consensus (GECCO) COVID-19 Research Data Set Using an Interdisciplinary, Consensus-Based Workflow: Data Set Development Study.使用基于跨学科共识的工作流程为德国新冠共识（GECCO）新冠研究数据集开发可互操作的特定领域扩展：数据集开发研究
JMIR Med Inform. 2023 Jul 18;11:e45496. doi: 10.2196/45496.
9
Inactivated SARS-CoV-2 booster vaccine enhanced immune responses in patients with chronic liver diseases.灭活的 SARS-CoV-2 加强疫苗增强了慢性肝病患者的免疫应答。
Virol Sin. 2023 Oct;38(5):723-734. doi: 10.1016/j.virs.2023.07.005. Epub 2023 Jul 22.
10
Vaccine-induced correlate of protection against fatal COVID-19 in older and frail adults during waves of neutralization-resistant variants of concern: an observational study.在出现中和抗性关注变异株期间，老年和体弱成年人中疫苗诱导的针对致命性新冠病毒病的保护相关因素：一项观察性研究
Lancet Reg Health Eur. 2023 May 6;30:100646. doi: 10.1016/j.lanepe.2023.100646.
ChAdOx1 nCoV-19 和 BNT162b2 同源和异源加强免疫的安全性、反应原性和免疫原性：一项前瞻性队列研究。
Lancet Respir Med. 2021 Nov;9(11):1255-1265. doi: 10.1016/S2213-2600(21)00357-X. Epub 2021 Aug 13.
4
Spike-antibody waning after second dose of BNT162b2 or ChAdOx1.第二次接种BNT162b2或ChAdOx1后刺突抗体水平下降。
Lancet. 2021 Jul 31;398(10298):385-387. doi: 10.1016/S0140-6736(21)01642-1. Epub 2021 Jul 17.
5
Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany.德国老年人对 BNT162b2 疫苗接种的迟发性抗体和 T 细胞反应。
Emerg Infect Dis. 2021 Aug;27(8):2174-2178. doi: 10.3201/eid2708.211145. Epub 2021 Jun 8.
6
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.BNT162b2 mRNA 新冠病毒疫苗在全国大规模疫苗接种环境中的效果。
N Engl J Med. 2021 Apr 15;384(15):1412-1423. doi: 10.1056/NEJMoa2101765. Epub 2021 Feb 24.
7
Adaptive immunity to SARS-CoV-2 and COVID-19.对 SARS-CoV-2 和 COVID-19 的适应性免疫。
Cell. 2021 Feb 18;184(4):861-880. doi: 10.1016/j.cell.2021.01.007. Epub 2021 Jan 12.